Patents by Inventor Ping Hui SZU

Ping Hui SZU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-claudin 18.2 antibodies
    Patent number: 11485782
    Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 1, 2022
    Assignee: Beijing Xuanyi Pharmasciences Co., Ltd.
    Inventors: Yuntao Song, Yi Ding, Chen Dong, Zhiwei Li, John Lippincott, Ping Hui Szu
  • CD80 VARIANT PROTEINS AND USES THEREOF
    Publication number: 20220227833
    Abstract: The present disclosure provides variant CD80 polypeptides that have altered affinity for their cognate binding partners, and immunomodulatory fusion proteins comprising the variant CD80 polypeptides. The present disclosure also provides pharmaceutical compositions comprising such polypeptides and/or proteins and methods for modulating immune responses and/or treatment of cancer, infectious diseases, and/or immunological diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 21, 2022
    Inventors: Yuntao SONG, Jianhui ZHOU, Yi DING, Ping Hui SZU, Chen DONG
  • ANTI-CLAUDIN 18.2 ANTIBODIES
    Publication number: 20210009686
    Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 14, 2021
    Inventors: Yuntao SONG, Yi DING, Chen DONG, Zhiwei LI, John LIPPINCOTT, Ping Hui SZU